Skip to main content

Trazodone Disease Interactions

There are 8 disease interactions with trazodone.


Antidepressants (applies to trazodone) angle closure glaucoma

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Glaucoma (Narrow Angle)

Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy. Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible. The use of these drugs in patients with untreated anatomically narrow angles should be avoided.


  1. "Product Information. Serzone (nefazodone)." Bristol-Myers Squibb (2001):
  2. "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC (2011):
  3. "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America (2013):

Antidepressants (applies to trazodone) mania

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Bipolar Disorder

All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder. Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.


  1. Kupfer DJ, Carpenter LL, Frank E "Possible role of antidepressants in precipitating mania and hypomania in recurrent depression." Am J Psychiatry 145 (1988): 804-8
  2. Schweizer E, Weise C, Clary C, Fox I, Rickels K "Placebo-controlled trial of venlafaxine for the treatment of major depression." J Clin Psychopharmacol 11 (1991): 233-6
  3. Khan A, Fabre LF, Rudolph R "Venlafaxine in depressed outpatients." Psychopharmacol Bull 27 (1991): 141-4
  4. "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories (2001):
  5. Warren M, Bick PA "Two case reports of trazodone-induced mania." Am J Psychiatry 141 (1984): 1103-4
  6. Theilman SB, Christenbury MM "Hypomania following withdrawal of trazodone." Am J Psychiatry 143 (1986): 1482-3
  7. Lennhoff M "Trazodone-induced mania." J Clin Psychiatry 48 (1987): 423-4
  8. Jabeen S, Fisher CJ "Trazodone-induced transient hypomanic symptoms and their management." Br J Psychiatry 158 (1991): 275-8
  9. Zmitek A "Trazodone-induced mania." Br J Psychiatry 151 (1987): 274-5
  10. Knobler HY, Itzchaky S, Emanuel D, Mester R, Maizel S "Trazodone-induced mania." Br J Psychiatry 149 (1986): 787-9
  11. "Product Information. Desyrel (trazodone)." Bristol-Myers Squibb (2001):
  12. Fontaine R "Novel serotonergic mechanisms and clinical experience with nefazodone." Clin Neuropharmacol 16 Suppl 3 (1993): s45-50
  13. "Product Information. Serzone (nefazodone)." Bristol-Myers Squibb (2001):
  14. Jeffries JJ, Aljeshi A "Nefazodone-induced mania." Can J Psychiatry 40 (1995): 218
  15. "Product Information. Remeron (mirtazapine)." Organon (2001):
  16. Montgomery SA "Safety of mirtazapine: a review." Int Clin Psychopharmacol 10(suppl 4 (1995): 37-45
  17. Dubin H, Spier S, Giannandrea P "Nefazodone-induced mania." Am J Psychiatry 154 (1997): 578-9
  18. "Product Information. Qelbree (viloxazine)." Supernus Pharmaceuticals Inc (2021):
View all 18 references

Nefazodone/trazodone (applies to trazodone) seizures

Moderate Potential Hazard, Moderate plausibility.

The use of most antidepressants is associated with a risk of seizures. There have been only rare reports of convulsions, including grand mal seizures, following the administration of nefazodone or trazodone. Although a causal relationship has not been established, therapy with these agents should be administered cautiously in patients with a history of seizures.


  1. Bowdan ND "Seizure possibly caused by trazodone HCl." Am J Psychiatry 140 (1983): 642
  2. Hohly EK, Martin RL "Increased seizure duration during ECT with trazodone administration." Am J Psychiatry 143 (1986): 1326
  3. Lanes T, Ravaris CL "Prolonged ECT seizure duration in a patient taking trazodone." Am J Psychiatry 150 (1993): 525
  4. Lefkowitz D, Kilgo G, Lee S "Seizures and trazodone therapy." Arch Gen Psychiatry 42 (1985): 523
  5. Tasini M "Complex partial seizures in a patient receiving trazodone." J Clin Psychiatry 47 (1986): 318-9
  6. Patel HC, Bruza D, Yeragani V "Myoclonus with trazodone." J Clin Psychopharmacol 8 (1988): 152
  7. "Product Information. Desyrel (trazodone)." Bristol-Myers Squibb (2001):
  8. "Product Information. Serzone (nefazodone)." Bristol-Myers Squibb (2001):
View all 8 references

Phenylpiperazine antidepressants (applies to trazodone) suicidality

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Bipolar Disorder, Depression

Adults, young adults and children patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior. Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes. Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset. Phenylpiperazine antidepressants are not approved for use in pediatric patients.


  1. "Product Information. Desyrel (trazodone)." Bristol-Myers Squibb (2001):
  2. "Product Information. Serzone (nefazodone)." Bristol-Myers Squibb (2001):

Trazodone (applies to trazodone) cardiovascular disease

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Hyperthyroidism, Arrhythmias

Although less cardiotoxic than the tricyclic antidepressants, trazodone may be arrhythmogenic in some patients with cardiac disease. The use of trazodone has been associated with the occurrence of arrhythmias, including PVCs, ventricular couplets, ventricular tachycardia, atrial fibrillation, and heart block. Myocardial infarction has been reported. Trazodone should not be used during the acute recovery phase following myocardial infarction, and should be administered only with extreme caution in patients with hyperthyroidism and/or cardiovascular disease. Close monitoring of cardiovascular status, including ECG changes, is recommended at all dosages. Many of the newer antidepressants, including bupropion and the selective serotonin reuptake inhibitors (SSRIs), are considerably less or minimally cardiotoxic and may be appropriate alternatives.


  1. Vlay SC, Friedling S "Trazodone exacerbation of VT." Am Heart J 106 (1983): 604
  2. McCracken J, Kosanin R "Trazodone administration during ECT associated with cardiac conduction abnormality." Am J Psychiatry 141 (1984): 1488-9
  3. Rausch JL, Pavlinac DM, Newman PE "Complete heart block following a single dose of trazodone." Am J Psychiatry 141 (1984): 1472-3
  4. Lippmann S, Bedford P, Manshadi M, Mather S "Trazodone cardiotoxicity." Am J Psychiatry 140 (1983): 1383
  5. Irwin M, Spar JE "Reversible cardiac conduction abnormality associated with trazodone administration." Am J Psychiatry 140 (1983): 945-6
  6. Janowsky D, Curtis G, Zisook S, Kuhn K, Resovsky K, Le Winter M "Ventricular arrhythmias possibly aggravated by trazodone." Am J Psychiatry 140 (1983): 796-7
  7. White WB, Wong SH "Rapid atrial fibrillation associated with trazodone hydrochloride." Arch Gen Psychiatry 42 (1985): 424
  8. Vitullo RN, Wharton JM, Allen NB, Pritchett EL "Trazodone-related exercise-induced nonsustained ventricular tachycardia." Chest 98 (1990): 247-8
  9. Aronson MD, Hafez H "A case of trazodone-induced ventricular tachycardia." J Clin Psychiatry 47 (1986): 388-9
  10. Pellettier JR, Bartolucci G "Trazodone and cardiovascular side effects." J Clin Psychopharmacol 4 (1984): 119
  11. Janowsky D, Curtis G, Zisook S, Kuhn K, Resovsky K, Le Winter M "Trazodone-aggravated ventricular arrhythmias." J Clin Psychopharmacol 3 (1983): 372-6
  12. van de Merwe TJ, Silverstone T, Ankier SI, Warrington SJ, Turner P "A double-blind non-crossover placebo-controlled study between group comparison of trazodone and amitriptyline on cardiovascular function in major depressive disorder." Psychopathology 17 (1984): 64-76
  13. Himmelhoch JM, Schechtman K, Auchenbach R "The role of trazodone in the treatment of depressed cardiac patients." Psychopathology 17 (1984): 51-63
  14. Glassman AH "The newer antidepressant drugs and their cardiovascular effects." Psychopharmacol Bull 20 (1984): 272-9
  15. "Product Information. Desyrel (trazodone)." Bristol-Myers Squibb (2001):
View all 15 references

Trazodone (applies to trazodone) hyponatremia

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Dehydration, SIADH

Treatment with trazodone may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). Caution should be used when treating patients at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted. Discontinuation of trazodone should be considered in patients with symptomatic hyponatremia and appropriate medical intervention should be instituted.


  1. "Product Information. Desyrel (trazodone)." Bristol-Myers Squibb (2001):

Trazodone (applies to trazodone) hypotension

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Dehydration, Ischemic Heart Disease, History - Myocardial Infarction, Diarrhea, Vomiting, Cerebrovascular Insufficiency, History - Cerebrovascular Disease

Trazodone has alpha-1 adrenergic blocking activity and may cause hypotension (including orthostatic hypotension) in approximately 5% of patients. Therapy with trazodone should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke. Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with trazodone. Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.


  1. Spivak B, Radvan M, Shine M "Postural hypotension with syncope possibly precipitated by trazodone." Am J Psychiatry 144 (1987): 1512-3
  2. "Product Information. Desyrel (trazodone)." Bristol-Myers Squibb (2001):

Trazodone (applies to trazodone) renal/liver disease

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Trazodone undergoes metabolism in the liver. The metabolites, at least one of which is pharmacologically active, are excreted by the kidney. There are no data available concerning the pharmacokinetic disposition of trazodone or its metabolites in patients with renal and/or liver disease. Therapy with trazodone should be administered cautiously in patients with significantly impaired renal or hepatic function. Dosage adjustments may be necessary.


  1. Nilsen OG, Dale O "Single dose pharmacokinetics of trazodone in healthy subjects." Pharmacol Toxicol 71 (1992): 150-3
  2. Greenblatt DJ, Friedman H, Burstein ES, et al. "Trazadone kinetics: effect of age, gender, and obesity." Clin Pharmacol Ther 42 (1987): 193-200
  3. "Product Information. Desyrel (trazodone)." Bristol-Myers Squibb (2001):

Trazodone drug interactions

There are 609 drug interactions with trazodone.

Trazodone alcohol/food interactions

There is 1 alcohol/food interaction with trazodone.

Report options

Share by QR Code
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.